Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share profits in the United States (40% PTC and 60% Novartis) and pay tiered royalties on ex-US sales.
The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
News Medical on MSN12h
Heart medication may slow the progression of Huntington's diseaseResearch indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
A common heart drug has shown promise to delay the onset of Huntington's disease -- a progressive and inherited brain ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...
After years of setbacks, biotechs are advancing treatments for Huntington’s disease, offering new hope as clinical studies ...
Huntington's Disease is one of the most devastating diseases out there and many people have never heard of it. Actor WIll ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback